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When processing sensory signals, the brain must account for noise, both noise in the stimulus and that arising from within its own
neuronal circuitry. Dopamine receptor activation is known to enhance both visual cortical signal-to-noise-ratio (SNR) and visual per-
ceptual performance; however, it is unknown whether these two dopamine-mediated phenomena are linked. To assess this, we used
single-pulse transcranial magnetic stimulation (TMS) applied to visual cortical area V5/MT to reduce the SNR focally and thus disrupt
visualmotiondiscriminationperformance to visual targets located in the same retinotopic space. Thehypothesis that dopamine receptor
activation enhances perceptual performance by improving cortical SNR predicts that dopamine activation should antagonize TMS
disruption of visual perception.We assessed this hypothesis via a double-blinded, placebo-controlled study with the dopamine receptor
agonists cabergoline (a D2 agonist) and pergolide (a D1/D2 agonist) administered in separate sessions (separated by 2 weeks) in 12
healthy volunteers in a William’s balance-order design. TMS degraded visual motion perception when the evoked phosphene and the
visual stimulus overlapped in time and space in the placebo and cabergoline conditions, but not in the pergolide condition. This suggests
that dopamine D1 or combined D1 and D2 receptor activation enhances cortical SNR to boost perceptual performance. That local visual
cortical excitability was unchanged across drug conditions suggests the involvement of long-range intracortical interactions in this D1
effect. Because increased internal noise (and thus lower SNR) can impair visual perceptual learning, improving visual cortical SNR via
D1/D2 agonist therapy may be useful in boosting rehabilitation programs involving visual perceptual training.
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Introduction
Noise is a feature of the nervous system and originates both ex-
ternally from the variability of the stimulus itself and internally
fromneuronal activity (Arieli et al., 1996; Cavanaugh et al., 2015)
The brain deals with noisy inputs by averaging information over
repeated trials and by using an expectation about the structure of
noise in sensory inputs (Ermentrout et al., 2008). Alterations in
internal noise in cerebral cortical circuits may be important clin-
ically because alterations in internal noise may play a critical role
in mediating recovery in perceptual functioning after brain in-
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Significance Statement
In this study, we address the issue of whether dopamine activation improves visual perception despite increasing sensory noise in
the visual cortex. We show specifically that dopamine D1 (or combined D1/D2) receptor activation enhances the cortical signal-
to-noise-ratio to boost perceptual performance. Together with the previously reported effects of dopamine upon brain plasticity
and learning (Wolf et al., 2003; Hansen and Manahan-Vaughan, 2014), our results suggest that combining rehabilitation with
dopamine agonists could enhance both the saliency of the training signal and the long-term effects on brain plasticity to boost
rehabilitation regimens for brain injury.
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jury (Cavanaugh et al., 2015). It follows that interventions that
modulate internal noise in neural cerebral cortical circuits may
aid recovery from brain injury and potentially boost rehabilita-
tion of patients.
Dopaminergic activation improves the cortical neuronal
signal-to-noise ratio (SNR) (Winterer and Weinberger, 2004;
Kroener et al., 2009) and enhances visual perceptual performance
(Mu¨ller et al., 1998; Noudoost and Moore, 2011). However, it is
unknown whether this dopamine enhancement of visual percep-
tual performance results from a dopamine-induced increase in
SNR. This predicts that dopaminergic activation would reduce
the disruptive effects of increased neuronal noise on perceptual
performance. Providing evidence linking dopaminergic en-
hancement of SNR and perceptual functioning could support a
mechanistic-based approach to pharmacological boosting of re-
habilitation programs.
We set out to assess the impact of dopaminergic modulation
of perceptual functioning in healthy volunteers but reproducing
high internal noise states (and lowered SNR) by applying focal
single-pulse transcranial magnetic stimulation (TMS) to the vi-
sual cortex (Ruzzoli et al., 2010). When applied to the visual
cortex at sufficient intensity, TMSdegrades visual perceptual per-
formance transiently for visual targets located in the retinotopic
space of the stimulated brain region. The hypothesis that dopa-
minergic enhancement of visual perceptual performance results
from a cortical SNR improvement would predict that dopamine
activation should reverse (or limit) the expected noise-related
degradation of visual perceptual performance artificially im-
posed by TMS (or, by extrapolation, by disease).
To test this prediction, we assessed the impact of TMS on a
standard visual perceptual task requiring subjects to indicate the
net direction ofmotion (right vs left) of a cloud of dotsmoving in
coherent motion embedded within a cloud of randomly moving
dots (Braddick, 1974; random dot kinematogram or RDK). The
RDK task difficulty can be titrated by changing the proportion of
coherent versus randommotion dots (Fig. 1A). Applying TMS to
visual cortex disrupts performance in the RDK task when at
least two conditions are concurrently satisfied: (1) when the
visual space occupied by the RDK overlaps with the retino-
topic space of the stimulated brain region, which is indicated
by the location of the TMS-evoked “phosphene” (a perceived
flash of light occurring after visual cortical TMS stimulation)
overlapping the location of the RDK; and (2) when there is
adequate temporal overlap between RDK onset and the TMS
pulse. When these two conditions are met, the same brain
region is stimulated at the same time by both the visual stim-
ulus (RDK) and the TMS pulse.
A further open question is whether any observed dopaminer-
gic effect on visual cortical SNR is mediated locally (i.e., in the
visual cortex). Recent single-neuron animal data suggest that the
effects of dopamine upon visual cortical functioning, including
its effect upon SNR, are mediated by mechanisms distant to the
visual cortex (Zaldivar et al., 2014). For example, modulating
dopamine D1 activity in primate prefrontal cortex affects visual
cortical neuronal responsiveness (Noudoost and Moore, 2011).
Therefore, in addition to using TMS to introduce noise to de-
grade visual performance, we also used it to assess any change in
local (i.e., V5/MT) baseline visual cortical responsivity thatmight
arise after dopaminergic activation and thus determine whether
changes in visual perceptual performance relate to changes in
local SNR (i.e., in visual cortex).
Materials andMethods
General method
To model the situation of increased neural noise in the visual cortex, we
applied single-pulse TMS. Because TMS modulates cortical function
transiently (50 ms; Cowey and Walsh, 2001), nonspecific effects of
TMS can be controlled by varying the overlap between a visual stimulus
and the time of TMSpulse onset. Figure 1 demonstrates the experimental
method by which we assessed the effect of TMS upon visual perceptual
function across space and time.
We ran two Experiments: A and B. The results of Experiment A were
used to refine the stimulus parameters for Experiment B. In Experiment
A, in two separate sessions, we compared the impact of threshold versus
suprathreshold left V5/MT cortical TMS on visual motion discrimina-
tion. Experiment A showed that suprathreshold TMS was more disrup-
tive of visual motion discrimination performance than threshold TMS.
Therefore, in Experiment B, we used suprathresholdTMS atV5/MT to
disrupt visual motion discrimination performance and assessed how this
TMS disruption was affected by pharmacological dopamine receptor
activation. There were three drug conditions in Experiment B: (1) pla-
cebo (lactose, a disaccharide sugar), (2) cabergoline (a dopamine D2
receptor agonist) at 1 mg, and (3) pergolide (a dopamine D1 and D2
agonist) at 500 g. The doses of cabergoline and pergolide chosen took
into account the doses used in prior studies, the dose-related side effects
of both drugs, and the need tomaintain clinical dose equivalents between
pergolide and cabergoline (Reichmann et al., 2003). Previous studies
have used cabergoline doses of up to 1.5 mg (Norbury et al., 2013),
requiring a pergolide dose equivalent of 1000 g, a dose likely to cause
excessive symptoms. We thus chose an intermediate cabergoline dose of
1 mg, providing a clinical equivalent for pergolide of 500 g. To avoid
drug side effects, we adapted a clinical protocol (Jansen et al., 2001) used
for the rapid titration of pergolide therapy in Parkinson’s disease (PD).
Therefore, all participants were prescribed domperidone 20 mg 3 times
per day for 3 d before testing and were given additional domperidone
doses on the day of testing (up to 60 mg that day). To maintain double
blinding, the drug capsules (containing placebo, pergolide, or cabergo-
line) were made up by a pharmacological laboratory and packaged in
identical inert shells. Participants were tested on three separate sessions
on different days with sessions separated by a minimum of 14 d to ac-
count for the drug half-lives in the systemic circulation (Fariello, 1998;
Rascol, 1999; Del Dotto et al., 2003; Agu´ndez et al., 2013). To balance
order effects, we randomized the order of drug administration using a
William’s balanced order design. The randomization list was drawn up
by a college staff member not involved in the study and provided to the
pharmacy, which then dispensed the drugs on a named-volunteer basis
according to the list.
We minimized within-subject, intersession performance variability,
and between-subject variability in three ways. First, the variability in
TMS location was minimized using neuronavigation (see “TMS target
localization” section below). Second, the variability in visual cortical
responsiveness (e.g., due to learning effects or differences in vigilance)
was controlled by calibrating the TMS intensity at every session (see
“TMS-evoked phosphene threshold determination” section below), and,
finally, the baseline visual motion coherence was titrated to a fixed visual
perceptual response level at the start of every session (see “Baseline visual
motion threshold determination” section below). Furthermore, we
asked participants to complete a self-administered questionnaire on vig-
ilance after drug administration, in which they were asked to indicate on
a line where they felt themselves to be between two extreme states as
follows: alert – drowsy; calm – excited; strong – feeble; muzzy – clear-
headed; well-coordinated – clumsy; lazy – energetic; contented – discon-
tented; troubled – tranquil;mentally slow – quick-witted; tense – relaxed;
attentive – dreamy; incompetent – proficient; happy – sad; aggressive –
friendly; interested – bored; and withdrawn – outgoing.
This method has been used previously to measure participants’ sub-
jective feelings before and after sleep (Herbert et al., 1976). The scores
were quantified by measuring the distance for each response and con-
verting it into a percentage of the total length of the line.
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TMS target localization
Single-pulse TMS was delivered using a MagPro X100 stimulator
(MagVenture) via an MC-B70 Butterfly coil (169 112 33 mm) held
in place over the region of interest by an adjustable coil holder. Because
previous TMS studies had suggested a relative lateralization of motion
processing within the left hemisphere (Stewart et al., 2001; Beckers and
Homberg, 1992), this experiment used left V5/MT for all stimulation.
Area V5/MT was initially located functionally via the induction of
moving phosphenes, a provenmethod used previously in studies of pho-
sphene perception (Seemungal et al., 2013; Stewart et al., 2001). Briefly, a
Figure 1. Methods.A, Schematic of the visual stimuli used throughout the experiments. Moving dotswith a given coherence (percentage of dotsmoving either to the left or the rightwith the remainder
movingwith randomdirections)werepresented ina5°5°of visual angleapertureonablack screen for200ms. The coherenceofdotmotion remainedconstant across trials andequalnumbersof trialswith
leftwardor rightwardmotionwerepresented.B, Each trial consistedof a visual stimulus (at time0) anda TMSpulse (lighteningbolt) thatwaspresentedbefore, coincidentwith (Experiments 1 and2), or after
(Experiment 2 only) the onset of the visual stimulus. Dots appeared randomly on the nonoverlapping or overlapping visual space.C, Single session in Experiment 2.
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physical landmark over the left hemisphere 3 cm dorsal and 5 cm lateral
to the inionwas used as an initial starting point.With subjects in the dark
andwith their eyes open, the coil wasmovedmanually around this region
until subjects reliably perceived moving phosphenes in the right lower
quadrant of their visual field, overlapping a region where subsequent
visual stimuli would be presented in the experiment. Once area V5/MT
was functionally located, its specific 3D coordinates relative to the
subject’s cerebral cortex were obtained with a neuronavigation system
(BrainVoyager) using individual T1-weighted MRI brain scans. Brain-
Voyager QX 2.6.1 (Brain Innovation) was used to construct 3D head
surface and left-hemisphere brain models (“meshes”) from structural
T1-weighted 3 tesla MRI scans of subjects’ brains. This setup allowed the
identified V5/MT stimulation point to be saved as a location on the head
surface, so themaintenance of the same target could be ensured through-
out the experiment and across sessions. This consistency across sessions
of targeting the same stimulated area V5/MT in a given subject further
reduced response variability.
TMS-evoked phosphene threshold determination
At the beginning of each experimental session, we calibrated the required
TMS intensity. For Experiment A, we determined the TMS intensity that
induced phosphenes with a probability of 50% (threshold) and 79%
(suprathreshold). For Experiment B, we only determined the suprath-
reshold intensity that elicited a 79% phosphene probability. Subjects
were asked to fixate on a fixation cross on an otherwise dark screen. After
every TMS pulse, they indicated “yes” or “no” as to whether they ob-
served a phosphene via button press. An adaptive QUEST staircase pro-
cedure (Watson and Pelli, 1983) was used over 40 trials to converge on
the threshold/suprathreshold TMS intensity. This calibration procedure
was run twice, first as a practice block and then to yield the coherence
values used for the experimental session. We also asked subjects to indi-
cate where on the screen they observed the phosphene and this position
was used for the presentation of the visual stimulus (see next section).
Visual motion stimuli (RDK)
The visual motion stimuli consisted of a black background with a 5°
diameter “cloud” of 50 circular moving dots with dots of angular diam-
eter 2° (4 pixels) and dot velocity of 12°/s. The dot cloud was presented
for 200 ms to either the left or right of the midline in a randomized
balanced order. The right hemifield visual stimulus location was pro-
grammed to overlie that of the subject’s observed phosphene. The visual
stimulus in the left hemifield was positioned at the same latitude and at
equal distance from the midline relative to the right hemifield visual
stimulus.
The visual stimulus consisted of an RDK with two populations of
moving dots: one moving coherently to the right or left and another
moving randomly. The relative ease of detecting the coherent population
dot direction (right vs left) was modulated by altering the number of
coherentmoving dots to thosemoving randomly. The visual stimuli were
presented on a 22 inch flat cathode ray tube display (Mitsubishi Super-
Bright Diamondtron DP2070SB) with a resolution of 1024 768 pixels
and a refresh rate of 85 Hz. PsychToolbox (Brainard, 1997; Pelli, 1997)
was used to present the experimental stimuli, trigger theTMS, and record
subject responses.
Baseline visual motion threshold determination
The proportion of coherently moving dots in the RDK was titrated so
that subjects correctly identified the coherent dot motion direction with
a 79% probability at baseline. This was done immediately after obtaining
the TMS threshold determination. This procedure obtained the subject’s
threshold of perception for motion in each direction (right and left)
before the experiment. The same adaptive QUEST staircase algorithm
(Watson and Pelli, 1983) was used as was used for the TMS threshold
determination. This calibration procedure involved 80 trials (40 in the
left visual field and 40 in the right visual field) and was run twice, first as
a practice and then to yield the coherence values used for the experimen-
tal session.
General procedure
Subjects sat on a padded, height-adjustable chair in a darkened labora-
tory. They were dark adapted for 30 min and the room luminance level
was kept constant across all sessions. Subjects stabilized their head on a
fixed chin rest, with their eyes 40 cm from the monitor screen. After
aligning the TMS to the subject’s left V5/MT using neuronavigation, the
subject’s TMS phosphene threshold was obtained. The coherence values
for rightward and leftward global dot motion were then ascertained.
There were 32 trials per block in Experiment A and 48 trials per block
in Experiment B. Each trial consisted of the presentation of the visual
stimulus of moving dots (200 ms duration), with TMS applied at differ-
ent times relative to the onset of the visual stimulus (see individual pro-
cedures below). Subjects were instructed to indicate with a button press
via a two-alternate forced-choice design whether they perceived the dot
motion direction as rightward or leftward. Subjects were required to
fixate upon a continuously present, central fixation square of size 0.5°
0.5°. In all trials, TMS was applied to the left cerebral hemisphere. In
contrast, the visual stimulus was presented randomly to either the right
or left visual field. In addition, the net coherent dot motion direction
within the RDK was randomized between right and left. Dot motion
direction and the three different times of TMS were randomized and
balanced within a single block. The response was prompted by the fixa-
tion square changing into a question mark and subjects were instructed
to respond as quickly as possible. Time between each trial was 5 s, with a
single block lasting 6.5 min. Breaks were taken as necessary between
blocks, but subjects were required to remain seated and were kept in the
dark.
Experiment A
Subjects. Twelve subjects (9 male) mean age 25 years  4 years with
normal or corrected-to-normal vision comprising students and staff of
Imperial College London participated in the study after informed con-
sent. Approval for the study was granted by the Charing Cross Hospital
Research Ethics Committee.
Procedure for Experiment A. Subjects completed one session of eight
experimental blocks of 32 trials each, totaling 256 trials for the whole
experiment. A session was initiated by determining the TMS threshold at
50% (threshold condition) and then at 79% (suprathreshold condition)
and a visual threshold at 79%. The visual thresholds were determined
twice to allow the subject one block as practice. Each experimental block
was run with either threshold or suprathreshold TMS, the order of the
blocks was alternated, and this in turn was counterbalanced across sub-
jects. A single trial consisted of the presentation of the visual stimulus of
moving dots (200 ms duration), with TMS asynchronously applied at
either 200 ms before or simultaneous with the onset of the visual stimu-
lus. The TMS time, dot direction, and visual presentation side was ran-
domized and balanced across conditions.
Experiment B
Subjects. Twelve healthy male volunteers (mean age: 25  4 years) with
normal or corrected-to-normal vision comprising students and staff of
Imperial College London participated in the study. One of these subjects
had participated in Experiment A, with experiments separated by 11
months.
Prolactin assay. Dopamine inhibits the secretion of prolactin by the
pituitary gland into the systemic circulation (Ben-Jonathan, 1985).
Changes in serum prolactin level will thus reflect the systemic bioavail-
ability of the ingested dopamine agonist for which absorption can be
variable. Subjects provided a baseline blood sample for serum prolactin,
after which they were administered one of the three randomized drugs
depending on their preassigned drug sequence. Dopamine agonists can
cause side effects such as somnolence and nausea (Frucht et al., 1999) by
stimulating dopamine receptors within the chemoreceptor trigger zone
of the area postrema, which, crucially, is outside of the blood–brain
barrier (Miller and Leslie, 1994; Borison, 1986; Stefanini and Clement-
Cormier, 1981). The peripherally acting dopamine D2 antagonist dom-
peridone, which does not cross the blood–brain barrier, suppresses
dopamine-related nausea without affecting central dopaminergic activ-
ity (Laduron and Leysen, 1979). It is standard clinical practice to pretreat
patients with domperidone before administering dopamine agonists to
reduce nausea (Jansen et al., 2001). In our study, all subjects took oral
domperidone (20 mg 3 times/d for 3 d) before testing. Note that one of
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the dopamine agonists, cabergoline, is a specific dopamineD2 agonist, so
domperidone, a selective D2 antagonist, will antagonize the cabergoline
effect in the periphery (but not in the brain). Because the pituitary gland
is perfused with systemic blood, the prolactin-suppressing effect of cab-
ergoline is attenuated by domperidone. In contrast, pergolide is a D1 and
D2 agonist, so it still has a potent prolactin suppressing effect via its D1
action despite the presence of the D2 blockade by domperidone.
Procedure for Experiment B. After baseline blood testing and drug ad-
ministration, the volunteers waited in a quiet room for 2 h to allow
absorption of the drug. During this period, they could read or work on a
computer. Serum prolactin was again sampled 2 h after administration
because the peak plasma concentration of pergolide is reached after 1–3 h
and that for cabergoline after 2–3 h (Agu´ndez et al., 2013). A final pro-
lactin sample was obtained at the end of the testing session, typically at
3.5 h after drug administration.
After neuronavigation setup, determination of the TMS intensity level
and titration of the visualmotion coherence level, the subjects completed
five blocks of 48 trials each, totaling 240 trials per session, and, as detailed
in “General method,” each subject participated in three sessions, one per
drug condition. A single trial consisted of the presentation of the visual
stimulus ofmoving dots (200ms duration), with TMS applied asynchro-
nously at 200 ms before, synchronous with, or 200 ms after the onset of
the visual stimulus. As before, the side of the RDK presentation (left or
right of the midline), the direction of coherent dot motion (leftward or
rightward) within the RDK cloud, and the onset times of TMS were
randomized and balanced across all 48 trials in a single block. All pretest
calibration and the testing itself lasted90 min.
Data analysis
Task performance in identifying the direction of coherentmotion within
the RDKwas quantified as the percentage correct. To correct for nonspe-
cific effects of TMS, a response gain was calculated as the percentage
correct for the condition in which the RDK and phosphene were over-
lapping (i.e., both RDK and phosphene in right hemifield) divided by the
percentage correct obtained when the RDK and phosphene were non-
overlapping (i.e., RDK in left hemifield and phosphene in right hemi-
field). The data were analyzed using MATLAB (The MathWorks) and
statistical calculations were performed using SPSS software with a signif-
icance level set at p  0.05. Two-tailed t test results are reported as
t(n 1) the test statistic, the p-value. Appropriate ANOVAswere used
for within-subject analyses and multivariate analyses were undertaken
when between-subject and group comparisons were being made.
Drift diffusion model
It was hypothesized that any dopamine-related enhancement of percep-
tual performance is related to an improvement in the visual cortical SNR.
Therefore, the subjects’ decision making process was modeled on the
two-alternative forced choice task (of choosing the net RDK coherent
motion direction) as a random walk process using a drift-diffusion
model (Ratcliff and McKoon, 1988), which incorporates a measure of
signal noise. At each time step during the decision making period, the
model posits an accumulation of evidence that is integrated until a choice
is made when a boundary is reached. The evidence accumulation is noisy
and therefore the process is stochastic. Themodel can be described by the
following equation:
n1  n    
where xt represents the accumulated evidence at time t, xt1 at time t 1,
 is the drift rate representing the speed at which the boundaries
are approached, and  represents Gaussian noise with variance . In the
model, a correct response is made when the accumulated evidence
reaches or surpasses a threshold level and an incorrect response is
made when the opposite boundary is reached.
The model was fitted to each participant’s performance (percentage cor-
rect and reaction time) for the placebo and pergolide conditions at simulta-
neous TMS and visual stimulus presentation only and for both overlapping
(RDK and phosphene on the same hemifield) and nonoverlapping (RDK
and phosphene on opposite hemifields) conditions. Three versions of the
model were run: (1) in the three-parameter model, we allowed the noise
parameter, the drift speed, and the boundary parameters to all vary; (2) in
the two-parametermodel,only thenoiseandthedrift speedparameterswere
allowed to vary; and (3) in the one-parameter model, we allowed only the
drift speed parameter to vary. The fminsearch algorithm in MATLAB was
used tominimize the sum of the 2 for the percentage correct response and
the reaction time. Finally, to assess which model best fit the data, the 2
measure for each of the three models, normalized by the number of the fit
parameters on a tri-plot, were fitted (Cavanaugh et al., 2002; El-Shamayleh
andMovshon, 2011; see Fig. 6). The distance from the external edge shows
whichmodel best fits the data as displayed in Figure 6 via isometric and side
projections.
Results
Experiment A
Consistent with the literature (Amassian et al., 1989), we found
that suprathesholdTMS (79%probability of a phosphene report)
impaired visual discrimination performance (t(11)  2.436, p 
0.033) when the visual stimulus and the TMS-evoked phosphene
occurred in the same visual space at the same time. Figure 2 shows
the percentage correct response rate for spatially overlapping and
nonoverlapping stimuli. It can be seen that, at both intensities,
TMS impairs performance for visual stimuli that overlap phos-
phenes in place and time compared with visual stimuli that do
not overlap phosphene location (and/or time of onset). A 2 2
2 repeated-measures ANOVA (factors: laterality, right vs left;
TMS strength, threshold vs suprathreshold; and time, TMS 200
ms before and simultaneous with visual stimulus) of the percent-
age correct data showed a significant effect of laterality (F 
6.031, p 0.032) and a significant interaction of laterality versus
time versus TMS strength (F 3.796, p 0.038).
In summary, TMS to area V5/MT impairs visual motion dis-
crimination performance when the visual stimulus overlaps the
TMS-evoked phosphene in space and time and this effect is more
prominent for suprathreshold TMS.
Figure 2. Results of Experiment 1.A, Overall effect of TMS on response rate in Experiment 1.
In the case when the TMS acted on the same visual space as the visual stimulus (overlapping),
the correct response ratewas suppressed comparedwithwhen the TMS and the visual stimulus
did not overlap. This was consistent for threshold (left panel) and suprathreshold TMS (right
panel) but most prominent for the 0ms condition with suprathreshold TMS (right panel).
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Experiment B
In Experiment B, we used the same experimental setup as Exper-
iment A with three notable differences. First, we used a single
TMS intensity set at suprathreshold intensity (79%probability of
a phosphene report). Second, we used three TMS onset latencies,
200 ms before, simultaneous with, and 200 ms after visual stim-
ulus onset. Finally, all subjects performed the task three times in
different sessions under different pharmacological conditions
(i.e., pergolide, cabergoline, and placebo).
For each of the drug conditions (Fig. 3), we performed a
repeated-measures 2  3 ANOVA with factors laterality of the
RDK position relative to the visual hemifield (i.e., right or left)
and time of TMS onset relative to the RDK onset (i.e., TMS 200
ms before, after, and simultaneously with the RDK).
For the placebo condition, we found that TMS impaired RDK
motion discrimination performance (Fig. 3) when the TMS-
induced phosphene and the RDK were simultaneously in the same
visual space (the right hemifield, i.e., the overlapping condition).
Specifically, we found a significantmain effect of laterality (F(1,11)
6.01; p  0.032), but not time, and there was no interaction. We
performeda singlepost hocpaired t test at t0ms (given the apriori
expectation on this time point), finding a significant difference at
p 0.05. Therefore, in the placebo condition in Experiment B, our
data supported previous findings in the literature that TMSdisrupts
visualmotionperceptionwhen theTMSand thevisualmotionstim-
ulus coincide in space and time.
For the cabergoline condition, we found a similar disrupting
effect of TMS at t 0mswith a significantmain effect of laterality
(F(1,11) 6.48; p 0.027) but not time. A single post hoc paired
test at t 0ms showed a nonsignificant (p 0.07) disruption of
visual motion perception by TMS for RDK stimuli that were
coincident with the TMS impulse in time and space.
In stark contrast, in the pergolide condition, we found no main
effect of laterality (p 0.81). Althoughnot indicated given the non-
significance of the ANOVA, for the purposes of comparison, we
found that a 2-tailed t test between the percentage correct for the
right versus left hemifield RDKs at t 0ms gave a p 1.0. Further-
more, a power calculation gave a sample size of	15,000 per sample
to enable the chance of finding a significant difference in perfor-
mance forRDKs in thedifferent hemifields at t0ms. In summary,
in the pergolide condition, we found no evidence for any difference
between the RDK performance between the two hemifields despite
the disrupting effect of TMS on the right hemifield performance at
t  0 ms. Note that we found a significant main effect of time
(F(2,10) 5.00; p 0.017). This effect was likely related to a general-
ized alerting effect ofTMS,whichproduces a loud click.ATMSclick
occurring before the visual stimulus (200 ms condition) will thus
increase readiness for the visual stimulus comparedwith the 0ms or
200 ms condition, in which the TMS click occurs after the visual
stimulus.
We also noted, however, that the overall performance in the
pergolide condition was reduced compared with the placebo and
the cabergoline conditions for both overlapping and nonoverlap-
ping stimuli. This general reduction in performance during the
pergolide condition was related to the reduced vigilance (sleepi-
ness is a recognized side effect of pergolide administration); the
group vigilance scores (where 0% represents maximum vigilance
and 100%minimum vigilance) were 47% for pergolide, 27% for
cabergoline, and 25% for placebo, with that for pergolide being
different from that for placebo (t(10)2.591, p 0.027). De-
spite this, Figure 4 shows that there were no differences in base-
line phosphene detection or visual perception between the three
drug conditions (one-way ANOVA for each task: TMS: F 
0.009, p  0.991; left visual stimuli: F  0.07, p  0.993; right
Figure 3. Results of Experiment 2. Shown is the effect of TMS on response rate under the different drug conditions in Experiment 2. In the placebo case, we see the same effect as in Experiment
1, with TMS lowering the response rate to overlapping stimuli compared with nonoverlapping stimuli. This effect is also seen under the cabergoline condition. However, when subjects took
pergolide, we find two effects: an overall suppression of response rate plus an improvement of the response to overlapping stimuli.
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visual stimuli: F  1.132, p  0.335). That the baseline assess-
ments were obtained after drug administration for each session
separately shows that drug administration did not affect either
baseline visual cortical excitability or visual motion detection
performance without TMS.
The bioavailability of pergolide was assessed bymeasuring the
fall in serum prolactin concentration obtained at three time
points within a session: on arrival, 2 h after drug administration,
and on completion of the experiment. We found that only per-
golide caused a significant change in prolactin (Fig. 5A) and this
was a 78% drop (p  0.0042). Note that, for the reasons ex-
plained in the Materials and Methods section, the coadministra-
tion of domperidone blocked the prolactin-lowering effect of
cabergoline (but had no effect on cabergoline’s central action),
so, as expected, we found no effect on prolactin levels with cab-
ergoline administration.
If pergolide’s effect on visual perceptual performance is me-
diated by its dopamine agonist activity, then this predicts that the
gain in performance at time t 0 ms (i.e., percentage correct for
right RDK/left RDK) achieved by subjects in the pergolide con-
dition should scalewith the relative fall in serumprolactin. Figure
5B shows the gain of the response in the pergolide condition
(overlapping/nonoverlapping percentage correct) for the 0 ms
condition versus the change in the prolactin level (end of exper-
iment measure). The plot shows that the visual perceptual re-
sponse gain was correlated with the fall in serum prolactin
(one-tailed t test: r2 0.29, t(10) 2.021, p 0.035). This indi-
cates that, the greater the pergolide-related dopamine activation,
the better the participants responded to visual stimuli that over-
lapped in time and space with the effects of TMS. Note that one
subject was omitted from this analysis because his baseline pro-
lactin level in the pergolide condition was more 	4 SDs away
from the groupmean (note that the baselinemeasures were taken
before anypergolide administration).This particular resultwas con-
firmed tobe spurious because this subject’s baseline serumprolactin
levels were within the normal range of the
other subjects for the other two conditions
(placebo and cabergoline).
Drift diffusion model
We fitted a drift diffusion model (see Ma-
terials andMethods) to our data from Ex-
periment B to assess which model
parameters (drift speed, noise level,
and/or boundary distance) were affected
by dopamine receptor activation. The re-
sults are plotted in terms of the corrected
2 values for each subject’s data fit to each
model on a tri-plot (Cavanaugh et al.,
2002; El-Shamayleh andMovshon, 2011).
This plot shows the three 2 values as the
end position of a vector in 3D space such
that the best fit is given by the edge closest
to the resulting position. For our results,
all of the data points are closest to the
three-parameter model edge (Fig. 6), in-
dicating that this model provides the best
account of the data given the differing
number of parameters between the mod-
els. Furthermore, on moving from the
three- to the two-parameter model (i.e.,
removing the boundary parameter), there
is comparatively less impact on fit com-
pared with moving from the two- to the one-parameter model
(i.e., removing noise). This indicates that themodulation of noise
variance by dopaminergic activation plays an important role in
the observed pergolide effect upon visual motion perceptual
performance.
Discussion
Recent evidence supports the notion that dopamine improves the
SNR in visual cortical networks (Winterer and Weinberger, 2004)
and enhances perceptual performance (Noudoost and Moore,
2011); however, it was not clear whether these dopamine-related
effects were linked through a common mechanism. We found that
dopaminergic receptor activation via pergolide (a D1/D2 agonist),
but not cabergoline (a D2 agonist), maintained visual perceptual
performance despite a TMS-induced increased SNR; that per-
golide’s effect on visual perceptual performance was dose depen-
dent; and that, in a drift-diffusion model, the noise parameter was
critical for explaining pergolide’s effect upon perceptual perfor-
mance. Together, our experimental andmodeled data strongly link
pergolide administration with improved perceptual performance
via a dopamine-related enhancement of neuronal SNR.
Although we found a specific effect of pergolide upon visual
motion perception versus cabergoline (and placebo), the ob-
served pergolide effect could have been mediated either by spe-
cific D1 activity or a combined D1/D2 action. This ambiguity of
pergolide action arises because some dopamine-mediated re-
sponses require the synergistic coactivation of D1 and D2 recep-
tors (Hasbi et al., 2011). The observed synergistic D1/D2 activity
has amolecular correlate because D1 andD2 receptors may form
heteromers (George and O’Dowd, 2007) with unique signaling
pathways distinct fromD1 or D2 receptors. Pergolide and caber-
goline also display serotonergic agonist activity, primarily at
5HT2 receptors (Millan et al., 2002); however, the relevant (albeit
scarce) literature does not support serotonin mediation of our
Figure4. Baseline RDK visualmotion coherence (percentage) for RDKs presented in the left visual space (A) or right visual space
(B) and baseline TMS intensity (C) for all three drug conditions (with TMS intensity expressed as a percentage of stimulator
maximum). At each of the 36 experimental sessions (12 subjects 3 different drug sessions), baseline TMS intensity and RDK
coherence was titrated to predetermined values (see Materials and Methods) to reduce intersubject and intersession variability.
Baseline TMS intensity and RDK coherence were not significantly different across the three drug conditions, including for RDKs
presented in the left visual space (A) or right visual space (B). Therefore, any difference across drug conditions cannot be due to
differences in baseline visual cortex V5/MT excitability (which is correlatedwith the TMS intensity required to elicit phosphenes at
a fixed probability) or RDK coherence.
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observed pergolide effect (Waterhouse et
al., 1990; Horton and Trobe, 1999; Carter
et al., 2004).
The use of TMS could affect subjects’
performances in a nonspecific manner via
effects upon arousal and/or directing atten-
tion. A TMS pulse is associated with a loud
click and for pulses that precede the presen-
tation of the visual stimulus, there could be
an improvement in the subject’s perfor-
mance simply as a result of the alerting effect
of the click. Suprathreshold TMS in the left
visual cortex also induces a right hemifield
phosphene that can direct attention toward
or away from the visual stimulus and thus
modulate sensory discrimination on this
basis alone. Our results, however, indicate
that, when the TMS preceded the stimulus,
there was no statistical difference between
the proportion of correct responses in the
overlapping versus nonoverlapping condi-
tions. Furthermore, there was no effect of
time in the nonoverlapping condition,
which served as our control condition on
the response rate, indicating that TMS was
not alerting or directing the attention of the
subject.
Another potential confound is the ef-
fect of dopaminergic activation in visual
pathways. For example, the retina con-
tains dopaminergic terminals (Kolb et al.,
1992; Zhang et al., 2007), so reduced or increased dopaminemay
affect retinal function. To control for these effects, in Experiment
B, we calibrated each participant’s baseline RDK performance
and TMS parameters at the start of each session, effectively re-
moving any changes in baseline cortical or retinal excitability that
could arise from the different drug conditions. Notably, however,
there were no differences across conditions of either the absolute
TMS intensity (indicating stable baseline visual cortical excitabil-
ity) or the percentage coherence in the RDK display needed to
obtain the required performance (indicating stable baseline vi-
sual perceptual performance). Therefore, the only difference
across conditions noted was for the pergolide condition when the
TMS and visual stimulus overlapped in time and space. This implies
Figure5. Assessingdopamine agonist bioavailability.A, Release of prolactin by the anterior pituitary gland is inhibitedbydopamine, so a reduction in serumprolactin levels can act as a surrogate
marker for the bioavailability of orally administered dopamine receptor agonists. Note that, to reduce nausea, we preadministered domperidone (over 3 d), a selective D2 receptor antagonist that
does not penetrate the blood–brain barrier. Because the pituitary gland is perfused by systemic blood, domperidone will tend to counteract dopamine agonists that possess primarily D2 agonist
activity (e.g., cabergoline, a selective D2 agonist), but not agonists with activity at other dopamine receptors (e.g., pergolide, a mixed D1/D2 receptor agonist). Correspondingly, for all subjects in
Experiment 2, administrationof placeboor cabergolinedidnot affect the level of prolactin across thedurationof the experimental session. In contrast, pergolide significantly reducedprolactin serum
concentration after its absorption compared with its baseline level. B, Furthermore, this change in prolactin correlated with the gain in the subjects’ response rate (nonoverlapping/overlapping).
Figure 6. The inclusion of noise variance is essential to account for the effects of dopamine on a drift-diffusion model of
perceptual decisionmaking. Shown is a tri-plotwith 2 values corrected by degrees of freedom for the threemodels: one inwhich
drift rate only is fit; one in which drift and noise variance are fit; and one in which drift rate, noise variance, and boundary position
are fit. The three axes vary from 0 to 1 and the points are color coded by the best 2 value for each subject.
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thatpergolide-relateddopaminergic activationconfers anadvantage
in sensory performance only when the sensory SNR is lowered—in
the present study, by TMS.
The brainmust deal with noise at all stages of sensory process-
ing. Noise is ubiquitous in the environmental signals that our
brains attempt to measure, as amply demonstrated by the chal-
lenging nature of discerning another person’s speech above the
hubbub of a cocktail party. Indeed, as a result of noisy cellular
processes such as ion channel activity, the sensory transduction
process that converts the stimulus to nervous impulses, as well as
the subsequent processing in sensory circuits in the CNS, all con-
tribute to noise in the signal and thus affect final outputs such as
decision making. Indeed, aging and brain disorders such as mi-
graine, schizophrenia, and PD all show evidence of elevated neu-
ronal noise and impaired sensory processing (Amick et al., 2003;
Stebbins et al., 2004;Winterer andWeinberger, 2004; Armstrong,
2011; Almer et al., 2012; Kim et al., 2013; Bates and Wolbers,
2014). For example, compared with healthy controls, schizo-
phrenic patients are less able to maintain visual motion discrim-
ination performance in the face of increased noise in the visual
motion signal (Chen et al., 2014). In contrast, we increased noise
in cerebral cortical circuits directly by applying visual cortical
TMS. The detrimental effect of such noise on visual processing
resulted in worsened visual motion direction discrimination
when the noise signal (TMS) overlapped the visual stimulus in
time and space (in the relevant brain region), but only for the
placebo and cabergoline and not the pergolide condition.
One means by which D1/2 receptor (pergolide) activation
could attenuate the effect of noise upon visual motion discrimi-
nation might be by reducing the responsiveness of the neuronal
population such that suprathreshold TMS input is effectively
rendered subthreshold. Indeed, subthreshold TMS enhances vi-
sual perceptual performance to boost the detection of visual stim-
uli (Abrahamyan et al., 2011). However, we found no difference
in baseline TMS intensities between drug conditions determined
during the calibration phase, potentially excluding changes in
responsiveness to TMS as an explanation for our results. Criti-
cally, however, in the baseline calibration, there was either TMS
or visual stimulation but not both. Because brain function is state
dependent, the altered TMS responsiveness with pergolide may
pertain to the condition of concurrent TMS and visual input
(Silvanto and Muggleton, 2008).
ThatD1(orcombinedD1/D2)receptoractivation improves sen-
sory perceptual performance in a state-dependent manner, such as
during high sensory noise, could provide a rationale for combining
dopamine agonists with physical therapy in patients with chronic
sensory disorders. A key principle of physical therapy is the use of
repetition to improve the performance of a task that is impaired as a
result of disease (or prior insult). In the visual domain, such practice
is called visual perceptual learning (VPL; Sasaki et al., 2010). Because
VPL improves perceptual performance, for example, visual motion
discrimination, then combining VPL with D1 or D1/D2 receptor
activation could enhanceVPL. This could thus benefit patients such
as those with stroke affecting the visual cortex, in whom there is an
impairment of visual perception in the visual space encoded by the
damaged cortex. Fortuitously, VPL can improve visual perception,
including visualmotion discrimination, after visual cortical damage
(Das et al., 2014). Critically, impaired visual perception after visual
cortical damage is linked to increased internal noise (Hayes and
Merigan, 2007) and, conversely,VPL-related improvement in visual
perceptual performance is related to a reduction in internal noise
(Cavanaugh et al., 2015). Our data thus offer a rationale in combin-
ing dopaminergic agonists to reduce internal noise to boost visual
cortical lesion patients’ response to VPL (Das et al., 2014).
Our data may also have implications for human diseases with
altered brain dopamine processing such as PD and schizophre-
nia. PD patients are deficient in brain dopamine and commonly
display visual perceptual abnormalities, with frankhallucinations
affecting up to one-third of PD patients (Sanchez-Ramos et al.,
1996). Interestingly, these visual symptoms aremore likely in low
light when there is high visual stimulus noise. The brain mecha-
nisms underlying visual hallucinations in PD are unknown but
are correlated with abnormal prefrontal functioning (Stebbins et
al., 2004). In fact, the prefrontal cortex modulates visual cortex
functioning because pharmacological antagonism of prefrontal
dopamine D1 receptors (but not D2 receptors) enhanced neuro-
nal response in primate area V4 to a similar degree as attention.
Together with our data, in high noise states, D1 agonists (via
fronto-occipital circuits) should lower visual neuronal respon-
siveness and thus improve information processing. However, PD
patients typically display worsened visual symptoms with dopa-
minergic administration. It is possible that deficits in fronto-
occipital pathways in PDmay attenuate (or reverse) the beneficial
effects of prefrontal dopamine D1 activation upon visual percep-
tual performance that we observed in healthy subjects. This sup-
position is supported by findings in schizophrenia, a disease of
elevated brain dopamine signaling. Schizophrenic patients, who
characteristically show an impairment of visual motion percep-
tion, display a reversal of the normal fronto-occipital activation
pattern during fMRI when observing visual motion (Chen et al.,
2008). Therefore, we suggest that combining dopamine D1 (or
D1/D2) activation with neuromodulation of fronto-occipital cir-
cuits could treat PD-related hallucinations.
In summary,wehave shown that pergolidedopaminergic activa-
tion improves visual motion discrimination performance under
conditions of increased sensory noise in the visual cortex. This, to-
gether with the well documented effects of dopamine upon brain
plasticity and learning (Wolf et al., 2003; Hansen and Manahan-
Vaughan, 2014), suggests that combining physical therapy regimens
with D1 (or mixed D1/D2) agonists could enhance both the acute
saliency of the training visual signal and the long-term effects upon
brain plasticity mechanisms (e.g., VPL), in effect “turbo charging”
rehabilitation regimens for brain injury.
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